Online inquiry

IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9147MR)

This product GTTS-WQ9147MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9147MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4230MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ8401MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ8367MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ9585MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ4898MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ13190MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ11797MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ1987MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW